Fresenius SE KGaA : Medical Care introduces multiFiltratePRO, a new therapy system for acute dialysis

Fresenius Medical Care AG & Co. KGaA, the world's largest provider of dialysis products and services, has launched multiFiltratePRO, a therapy system for continuous renal replacement therapy (CRRT), for the treatment of acute kidney failure in critically ill patients at intensive care units.

Everybody who has to fulfill demanding tasks with the help of technical devices during their daily clinical routine needs a sense of safety and reliability. The more extensive the tasks are the more important is the easy and intuitive handling of the complex technology. Fresenius Medical Care's multiFiltratePRO is specifically tailored to meet these needs.

Dominik Wehner, chief executive officer for Europe, Middle East and Africa commented: "User-friendly operations, reliability as well as the usage for various extracorporeal therapies are the key strengths of this new therapy system multiFiltratePRO. This powerful technology increases efficiency and ergonomics and is equally easy to operate."

A multitude of features supports physicians and caregivers who are increasingly experiencing raising workloads and high working pressure: a large touch screen monitor comprehensively displays all needed information; intuitive handling; fully integrated fluid heaters reliably provide the right temperature of the fluid; a "Care-Mode" prevents unnecessary alarms and a functional chassis allows easy mobility also in the narrow space at the bedside.

The multiFiltratePRO platform is based on modern technology and builds on substantial experience with our successfully established Ci-Ca® regional anticoagulation which results in less bleeding for the patients.

Dr. Olaf Schermeier, chief executive officer for Global Research and Development stated: "Over the time we expect to expand this new therapy platform. The reliable and simple user interface helps reducing the demand on personnel while providing the highest treatment quality. And spending less time with handling complex technology offers the opportunity to pay more attention to the patient itself."

For more information, visit www.multiIntenseCare.com.

###

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.6 million individuals worldwide. Through its network of 3, 396 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatments for 286,768 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

For more information visit the company's website at www.freseniusmedicalcare.com.

Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.